Tumor suppressor gene BLU is frequently downregulated by promoter hypermethylation in myelodysplastic syndrome

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 5, 2012, Pages 729-737

  Yang, Yujuan ^a   Zhang, Qingxia ^a   Xu, Feng ^a   Wu, Lingyun ^a   He, Qi ^a   Li, Xiao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

5 aza 2' deoxycytidine; BLU; Myelodysplastic syndrome; Promoter methylation; Tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; MESSENGER RNA; TUMOR SUPPRESSOR PROTEIN; ZMYND10 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLU GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; FEMALE; GENE ACTIVITY; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE SEQUENCE; GENETIC REGULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; CASE CONTROL STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84862287522     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1151-0     Document Type: Article

References (39)

1. Agathanggelou A, Dallol A, Zöchbauer-Müller S, Morrissey C, Honorio S, Hesson L, Martinsson T, Fong KM, Kuo MJ, Yuen PW, Maher ER, Minna JD, Latif F (2003) Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. Oncogene 22(10):1580-1588 (Pubitemid 36390607)
2. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P (2006) Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 76(1):23-32
3. Brait M, Sidransky D (2011) Cancer epigenetics: above and beyond. Toxicol Mech Methods 21(4):275-288
4. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108(2):419-425 (Pubitemid 44061337)
5. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P, Jones PA, Lübbert M (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 100(8):2957-2964
6. Garcia-Manero G (2010) Prognosis of myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program 2010:330-337
7. Greenberg PL (2011) Myelodysplastic syndromes: dissecting the heterogeneity. J Clin Oncol 29(15):1937-1938
8. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079-2088 (Pubitemid 27132124)
9. Grövdal M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Wallvik J, Tangen JM, Oberg G, Jacobsen SE, Hokland P, Porwit A, Hellström-Lindberg E (2007) Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res 13(23):7107-7112 (Pubitemid 350276895)
10. Gu J, Berman D, Lu C, Wistuba II, Roth JA, Frazier M, Spitz MR, Wu X (2006) Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 12(24):7329-7338 (Pubitemid 46095405)
11. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349(21):2042-2054 (Pubitemid 37448928)
12. Hesson L, Bièche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER, Latif F (2004) Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 23(13):2408-2419 (Pubitemid 38496796)
13. Issa JP (2010) Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 24(2):317-330
14. Ito M, Ito G, Kondo M, Uchiyama M, Fukui T, Mori S, Yoshioka H, Ueda Y, Shimokata K, Sekido Y (2005) Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett 225(1):131-139 (Pubitemid 40732776)
15. Iwai M, Kiyoi H, Ozeki K, Kinoshita T, Emi N, Ohno R, Naoe T (2005) Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome. Leukemia 19(8):1367-1375 (Pubitemid 41136330)
16. Kaiser J (2010) Genes link epigenetics and cancer. Science 330(6004):577
17. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106(8):1794-1803
18. Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP (2007) Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 109(2):265-273 (Pubitemid 46106241)
19. Karberg S (2009) Switching on epigenetic therapy. Cell 139(6):1029-1031
20. Lai HC, Lin YW, Chang CC, Wang HC, Chu TW, Yu MH, Chu TY (2007) Hypermethylation of two consecutive tumor suppressor genes, BLU and RASSF1A, located at 3p21.3 in cervical neoplasias. Gynecol Oncol 104(3):629-635
21. Lechner M, Boshoff C, Beck S (2010) Cancer epigenome. Adv Genet 70:247-276
22. Lerman MI, Minna JD (2000) The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The international lung cancer chromosome 3p21.3 tumor suppressor gene consortium. Cancer Res 60(21):6116-6133
23. Lorente A, Mueller W, Urdangarín E, Lázcoz P, Lass U, von Deimling A, Castresana JS (2009) RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol 19(2):279-292
24. Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, PXüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediateor high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Wnal results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 29(15):1987-1996
25. Nolte F, Hofmann WK (2010) Molecular mechanisms involved in the progression of myelodysplastic syndrome. Future Oncol 6(3):445-455
26. Olk-Batz C, Poetsch AR, Nöllke P, Claus R, Zucknick M, Sandrock I, Witte T, Strahm B, Hasle H, Zecca M, Stary J, Bergstraesser E, De Moerloose B, Trebo M, van den Heuvel-Eibrink MM, Wojcik D, Locatelli F, Plass C, Niemeyer CM, Flotho C, European Working Group of Myelodysplastic Syndromes in Childhood (EWOGMDS) (2011) Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome. Blood 117(18): 4871-4880
27. Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, Tsao SW, Tao Q (2004) The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 23(27):4793-4806 (Pubitemid 38859468)
28. Riquelme E, Tang M, Baez S, Diaz A, Pruyas M, Wistuba II, Corvalan A (2007) Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. Cancer Lett 250(1):100-106 (Pubitemid 46483848)
29. Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F (2010) Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther 10(1):9-22
30. Shaffer LG, Tommerup N (eds) (2005) An international system for human cytogenetic nomenclature. Basel, Switzerland
31. Shao Y, Zhang W, Zhang C, Wu Q, Yang H, Zhang J, Guan M, Wan J, Yu B (2010) High-resolution melting analysis of BLU methylation levels in gastric, colorectal, and pancreatic cancers. Cancer Invest 28(6):642-648
32. Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31(1):27-36
33. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28(4):605-613
34. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia- Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H (2009) Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27(23):3842-3848
35. Uchida T, Kinoshita T, Nagai H, Nakahara Y, Saito H, Hotta T, Murate T (1997) Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 90(4):1403-1409 (Pubitemid 27355412)
36. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100(7):2292-2302
37. Voso MT, D'Alò F, Greco M, Fabiani E, Criscuolo M, Migliara G, Pagano L, Fianchi L, Guidi F, Hohaus S, Leone G (2010) Epigenetic changes in therapy-related MDS/AML. Chem Biol Interact 184(1-2):46-49
38. Watanabe Y, Maekawa M (2010) Methylation of DNA in cancer. Adv Clin Chem 52:145-167
39. Yi Lo PH, Chung Leung AC, Xiong W, Law S, Duh FM, Lerman MI, Stanbridge EJ, Lung ML (2006) Expression of candidate chromosome 3p21.3 tumor suppressor genes and down-regulation of BLU in some esophageal squamous cell carcinomas. Cancer Lett 234(2):184-192